Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of PF-06751979 in Healthy Subjects
NCT02509117Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06751979 in Alzheimer's disease (AD) (5 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Day 19 and 1 more. Started Jul 2015; status: completed.
02
Drugs
PF-06751979
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02509117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509117.